GEN Exclusives

More »

GEN Poll

More »
May 07, 2013

Alzheimer’s Research

Baxter International’s drug candidate Gammagard is the latest Alzheimer’s therapeutic to fail in meeting its clinical endpoints. A number of other potential therapies have suffered similar fates. With these failures in mind, how can Alzheimer’s sufferers remain optimistic that relief is in sight?

Do you foresee a major breakthrough in the treatment of Alzheimer’s disease within the next 10 years?

Yes
 
  58.2%
No
 
  30.8%
Undecided
 
  11.0%

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

Be sure to take the GEN Poll

Using CRISPRs to Tame GMOs

With more climate-induced droughts and insect infestations on the horizon do you think technologies like CRISPR will change a lot of people’s minds about GMOs, including genetically engineered foods?

More »